N
Nandita Bose
Publications - 11
Citations - 690
Nandita Bose is an academic researcher. The author has contributed to research in topics: Medicine & Cancer research. The author has an hindex of 1, co-authored 1 publications receiving 586 citations.
Papers
More filters
Journal ArticleDOI
Activation of the innate immune receptor Dectin-1 upon formation of a /`phagocytic synapse/'
Helen S. Goodridge,Christopher N. Reyes,Courtney A. Becker,Tamiko R. Katsumoto,Jun Ma,Andrea J. Wolf,Nandita Bose,Anissa S.H. Chan,Andrew S. Magee,Michael E. Danielson,Arthur Weiss,John P. Vasilakos,David M. Underhill,David M. Underhill +13 more
TL;DR: The ‘phagocytic synapse’ now provides a model mechanism by which innate immune receptors can distinguish direct microbial contact from detection of microbes at a distance, thereby initiating direct cellular antimicrobial responses only when they are required.
Journal ArticleDOI
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
Anissa S.H. Chan,Takashi Kangas,Xiaohong Qiu,Mark Uhlik,Ross B. Fulton,Nadine Ottoson,Keith B. Gorden,Yumi Yokoyama,Michael E. Danielson,Trinda M. Jevne,Kyle S. Michel,Jeremy R. Graff,Nandita Bose +12 more
TL;DR: Pre-clinical mechanistic data supportive of Imprime demonstrate Imprime’s potential to orchestrate a broad, yet coordinated, anti-cancer immune response and complement existing cancer immunotherapies.
Proceedings ArticleDOI
1327 Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cells
Jeremy Drees,Anissa S.H. Chan,Yunfang Li,Takashi Kangas,Weiyu Zhang,M. Fumagalli,Iman Dewji,Kathryn T. Bieging-Rolett,Sho Fujisawa,Sharon Huang,Ben J. Harrison,Ashley LaCayo,Xiaohong Qiu,Nick Collette,Gemily Wang,Feven Tameire,Paulina M. Wojnarowicz,Crissy Dudgeon,Eric S. Lightcap,David Surguladze,Nandita Bose +20 more
TL;DR: HC-7366 as mentioned in this paper is a first-in-class, firstin-human GCN2 modulator that activates GCN 2, resulting in anti-tumor activity.
Journal ArticleDOI
Abstract A30: Activation of GCN2 by HC-7366 results in significant anti-tumor efficacy as monotherapy and in combination with Venetoclax in AML models
Feven Tameire,Paulina M. Wojnarowicz,Sho Fujisawa,Sharon Huang,O. Reilly,Crissy Dudgeon,Nick Collette,Jeremy Drees,Kathryn T. Bieging-Rolett,Takashi Kangas,Weiyu Zhang,M. Fumagalli,Iman Dewji,Yunfang Li,Anissa S.H. Chan,Xiaohong Qiu,Ben J. Harrison,Ashley LaCayo,Kirk A. Staschke,Alan C. Rigby,Savithri Ramurthy,Eric S. Lightcap,David Surguladze,Nandita Bose +23 more
TL;DR: Tameire et al. as mentioned in this paper developed HC-7366, a first-in-class, firstin-human GCN2 activator, and are currently evaluating it in a phase 1 clinical trial in solid tumors.
Journal ArticleDOI
Abstract 6231: Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer models
Feven Tameire,Paulina M. Wojnarowicz,Crissy Dudgeon,Sho Fujisawa,Sharon Huang,O. Reilly,Nick Collette,Jeremy Drees,Kathryn T. Bieging-Rolett,Takashi Kangas,Weiyu Zhang,M. Fumagalli,Iman Dewji,Yunfang Li,Anissa S.H. Chan,Xiaohong Qiu,Ben J. Harrison,Ashley LaCayo,Ricardo A. Cordova,Kirk A. Staschke,Alan C. Rigby,Savithri Ramurthy,Eric S. Lightcap,David Surguladze,Nandita Bose +24 more
TL;DR: Tameire et al. as mentioned in this paper developed HC-7366, a first-in-class, firstin-human GCN2 activator, and are currently evaluating it in a phase 1 clinical trial in solid tumors.